SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
First-in-class drug targeting a tumor protein achieves 52% response in hard-to-treat lung cancer, substantially exceeding historical survival benchmarks for this disease.
ABBV-706, a first-in-class ADC targeting SEZ6 (expressed on SCLC and neuroendocrine neoplasms), demonstrated a 52% objective response rate in 124 patients with relapsed/refractory SCLC with a median overall survival of 12.4 months at the recommended Phase 2 dose — substantially exceeding historical benchmarks for this notoriously difficult-to-treat disease. The recommended Phase 2 dose of 1.8 mg/kg Q3W was selected based on an optimal balance of durable tumor reduction, OS, and tolerability over the 2.5 mg/kg dose.
What the study was
- Study design
- Open-label Phase 1 dose escalation/expansion trial
- Population
- Adults with advanced solid tumors; primary cohort: relapsed/refractory SCLC
- Sample size
- 288
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature Medicine
Why it surfaced
SEZ6-targeting ADC achieves 52% ORR in R/R SCLC — a disease with <10% ORR on available salvage therapies — published in Nature Medicine; n=124 R/R SCLC cohort is unusually large for Phase 1 and provides meaningful efficacy signal; median OS 12.4 months at RP2D substantially above historical controls (~6-8 months for second-line SCLC).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.